<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00360854</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000481539</org_study_id>
    <secondary_id>CCLG-NAG-2005-09</secondary_id>
    <secondary_id>ITCC-003</secondary_id>
    <secondary_id>EU-20617</secondary_id>
    <secondary_id>CCLG-CPP-05-07</secondary_id>
    <secondary_id>ROCHE-MO18461</secondary_id>
    <secondary_id>EUDRACT-2004-005247-10</secondary_id>
    <nct_id>NCT00360854</nct_id>
  </id_info>
  <brief_title>Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma</brief_title>
  <official_title>Phase I Studies of TARCEVA™ (ERLOTINIB HYDROCHLORIDE, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With Irradiation in Newly Diagnosed Brain Stem Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving&#xD;
      erlotinib together with radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of erlotinib when&#xD;
      given alone or together with radiation therapy in treating young patients with refractory or&#xD;
      relapsed malignant brain tumors or newly diagnosed brain stem glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Establish the maximum tolerated dose of single-agent erlotinib hydrochloride in&#xD;
           pediatric patients with refractory or relapsed malignant brain tumors and in combination&#xD;
           with radiotherapy in pediatric patients with newly diagnosed brain stem glioma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine dose-limiting toxicities of these regimens.&#xD;
&#xD;
        -  Define the safety profile of these regimens.&#xD;
&#xD;
        -  Characterize the pharmacokinetic behavior of erlotinib hydrochloride in these patients.&#xD;
&#xD;
        -  Evaluate the efficacy of these regimens.&#xD;
&#xD;
        -  Correlate expression and mutations of epidermal growth factor receptor with treatment&#xD;
           response.&#xD;
&#xD;
      OUTLINE: This is a multicenter, nonrandomized, open-label, dose-escalation study of erlotinib&#xD;
      hydrochloride. Patients are assigned to 1 of 2 treatment groups according to disease.&#xD;
&#xD;
        -  Group 1 (refractory or relapsed malignant brain tumors): Patients receive oral erlotinib&#xD;
           hydrochloride once daily on days 1-21. Treatment repeats every 21 days in the absence of&#xD;
           unacceptable toxicity or disease progression.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of erlotinib hydrochloride until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity (DLT).&#xD;
&#xD;
        -  Group 2 (newly diagnosed brain stem glioma): Patients receive oral erlotinib&#xD;
           hydrochloride once daily on days 1-21. Treatment repeats every 21 days in the absence of&#xD;
           unacceptable toxicity or disease progression. Beginning on day 1, patients also undergo&#xD;
           radiotherapy 5 days a week for 6 weeks .&#xD;
&#xD;
      Cohorts of 1-2 patients receive escalating doses of erlotinib hydrochloride until the MTD is&#xD;
      determined. The MTD is defined as the dose resulting in 25% of patients experiencing DLT at 6&#xD;
      weeks.&#xD;
&#xD;
      Blood is collected for pharmacokinetic assessments and pharmacogenetic genotyping for&#xD;
      analysis of enzyme polymorphisms. Tumor tissue may be assessed for epidermal growth factor&#xD;
      receptor mutations.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 48 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2005</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of erlotinib hydrochloride when given alone and in combination with radiotherapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-limiting toxicities</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic behavior of erlotinib hydrocloride</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of expression and mutations of epidermal growth factor receptor with treatment response</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Histologically or cytologically confirmed malignant brain tumor&#xD;
&#xD;
                    -  Refractory to first-line therapy or relapsed after conventional therapy&#xD;
&#xD;
                    -  No effective conventional therapy exists&#xD;
&#xD;
               -  Histologically confirmed brain stem glioma&#xD;
&#xD;
                    -  Newly diagnosed disease&#xD;
&#xD;
                    -  No pilocytic glioma&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2 OR Lansky play scale 50-100%&#xD;
&#xD;
               -  Patients with motor paresis due to disease are eligible&#xD;
&#xD;
               -  Neurological deficits must be stable for ≥ 1 week&#xD;
&#xD;
          -  Life expectancy ≥ 8 weeks&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL&#xD;
&#xD;
          -  AST/ALT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN OR creatinine clearance ≥ 70 mL/min&#xD;
&#xD;
          -  No other serious, uncontrolled illness&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No organ toxicity ≥ grade 2 except alopecia and neurological symptoms due to disease&#xD;
&#xD;
          -  Must be able to take oral medication&#xD;
&#xD;
               -  Patients with newly diagnosed brain stem glioma with difficulty swallowing may be&#xD;
                  eligible&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No evidence of pulmonary dysfunction or pre-existing lung disease&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No severe cardiac pathology&#xD;
&#xD;
          -  No significant ophthalmologic abnormality including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Severe dry eye syndrome&#xD;
&#xD;
               -  Keratoconjunctivitis sicca&#xD;
&#xD;
               -  Sjögren's syndrome&#xD;
&#xD;
               -  Severe exposure keratitis&#xD;
&#xD;
               -  Any other disorder likely to increase the risk of corneal epithelial lesions&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  More than 6 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent warfarin&#xD;
&#xD;
          -  No other concurrent anticancer or investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darren Hargrave, MD</last_name>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Our Lady's Hospital for Sick Children Crumlin</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Child Health at University of Bristol</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Children's Hospital, Alder Hey</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middlesex Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W1T 3AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children NHS Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester and Manchester Children's University Hospitals NHS Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M27 4HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir James Spence Institute of Child Health</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Sheffield</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospital NHS Trust</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Belfast Hospital for Sick Children</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Aberdeen Children's Hospital</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH9 1LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital for Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>August 3, 2006</study_first_submitted>
  <study_first_submitted_qc>August 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2006</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>untreated childhood brain stem glioma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>childhood grade I meningioma</keyword>
  <keyword>childhood grade II meningioma</keyword>
  <keyword>childhood grade III meningioma</keyword>
  <keyword>childhood low-grade cerebral astrocytoma</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>recurrent childhood brain tumor</keyword>
  <keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
  <keyword>recurrent childhood pineoblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

